ZBH Stock Might Rise Following FDA Nod for Knee Implant Component
Zimmer Biomet's Persona SoluTion Porous Plasma Spray Femur gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.
ZBH Stock Gains From Receiving CE Mark for Persona Revision Knee System
Zimmer Biomet gets CE Mark Certification for Persona Revision Knee System, followed by the successful introduction in the United States and other markets.
Countdown to Zimmer (ZBH) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Zimmer (ZBH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metri...
ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
Zimmer Biomet's third-quarter results are likely to reflect the strength in its three business segments, namely Hips, Knees and S.ET.
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Cuts Revenue View
Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.
Zimmer Biomet (ZBH) Tops Q2 Earnings and Revenue Estimates
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $1.82 per share a year ago.
Zimmer Biomet: Brighter Prospects In H2 2024
Zimmer Biomet's share price has been under pressure in recent months due to soft growth, poor cash flows, and higher interest rates. Demographics, the rise of ASCs and technological advancements sh...
Zimmer Biomet (ZBH) to Broaden Knee Surgery Line With New Alliance
Zimmer Biomet (ZBH) joins forces with Think Surgical for the distribution of customized TMINI - Miniature Robotic System in the U.S. market.
Zimmer Biomet (ZBH) Procedure Recovery Aids Amid Macro Woes
Zimmer Biomet (ZBH) continues to record strong procedure volume in 2024 in both the Knees and Hips businesses, banking on an improved market scenario.
Zimmer Biomet Outlines Strategy to Deliver Above Market Growth at 2024 Investor Day
Presents Path for Compelling and Durable Topline Growth, Improved Operational Profitability and Increased Free Cash Flow Generation Details New Capital Allocation Priorities and Commitment to Strat...
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Zimmer Biomet (ZBH) Stock for Now
Strong procedure recovery and progress on the four-pillar strategy bode well for Zimmer Biomet (ZBH).
Zimmer Biomet Holdings, Inc. (ZBH) Q1 2024 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Keri Mattox - Chief Communications and Administration Officer Ivan Tornos - Pre...
Zimmer Biomet (ZBH) Q1 Earnings Beat, Margins Expand
Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER.
Zimmer (ZBH) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Zimmer (ZBH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare ...
Related Companies